Last update: Nov. 26, 2014


Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Opioid analgesic which is used for treatment of chronic pain.

At latest update, relevant data on its excretion into breast milk were not found.

Despite of a low molecular weight and a low serum-protein binding capacity that would favor excretion into the milk, its high value of volume distribution would permit a shorter permanence in the blood that would hamper its excretion.

A low oral bioavailability would hamper absorption from ingested mother's milk, except among newborn infants o prematures, who may attain an increased absorption capacity.

The risk for the infants would be minimized if the breast feed is avoided within 1 to 4 hours (non-depot formulation), or, within 3 to 6 hours (depot formulation) after taking medication.

Until more information on this drug is available, other options that are known to be safer are recommended, especially when the baby is a newborn or a premature.

Follow-up of symptoms as sedation or gastrointestinal disorders is recommended.


Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Tapentadol belongs to this group or family:


Main tradenames from several countries containing Tapentadol in its composition:


Variable Value Unit
Oral Bioavail. 32 %
Molecular weight 221 daltons
Protein Binding 20 %
VD 540 l/Kg
Tmax 1,25 (Retard: 3 - 6) hours
T1/2 4 (Retard: 6) hours


  1. [No authors listed] Tapentadol. Acute or chronic pain: no therapeutic advance. Prescrire Int. 2014 Abstract
  2. AEMPS. Tapentadol. Ficha técnica. 2013 Full text (in our servers)
  3. CADIME. Tapentadol. Ficha técnica. 2012 Full text (in our servers)
  4. WHO. Expert Committee on Drug Dependence Pre-Review Report. Thirty-fifth Meeting. Hammamet, Tunisia. 2012 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by El Parto Es Nuestro from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM